| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;100:II-361.)
© 1999 American Heart Association, Inc.
Myocardial Protection and Vascular Biology |
B Nuclear Translocation Without Degradation of I
B
From the Department of Surgery, University of Washington, Seattle.
Correspondence to Timothy H. Pohlman, Department of Surgery, University of Washington, Harborview Medical Center, Box 359796, Seattle, WA 98104-2924. E-mail tpohlman{at}u.washington.edu
| Abstract |
|---|
|
|
|---|
B, an
oxidative stressresponsive transcription factor, participates
transiently in the control of gene expression. The cellular mechanisms
that mediate NF-
B activation during ischemia (and during
reperfusion in the course of treating ischemia) are not
known.
Methods and ResultsTo investigate the NF-
B activation induced
during oxidative stress, we examined human cardiac tissue obtained
during surgical procedures requiring cardiopulmonary bypass. In
vitro, we examined human umbilical vein endothelial
cells (HUVECs) exposed to hypoxia,
reoxygenation after hypoxia, or a reactive
oxygen intermediate (H2O2). Electrophoretic
mobility shift assays performed on right atrial tissue revealed
prominent NF-
B activation after hearts had been exposed to
ischemia and reperfusion. The assays also showed that NF-
B
activation was observed in hypoxic HUVECs after
reoxygenation and in cultures treated with
H2O2 (500 µmol/L). Pervanadate (200
µmol/L) also induced marked NF-
B activation in HUVECs, indicating
that H2O2-induced NF-
B activation is
potentiated by the inhibition of tyrosine phosphatases. Western
blotting of cytoplasmic I
B
demonstrated that NF-
B activation
induced by oxidative stress was not associated with I
B
degradation. In contrast, tumor necrosis factor-
induced
NF-
B activation occurred in concert with degradation of I
B
.
Inhibition of I
B
degradation with a proteasome
inhibitor, MG-115, blocked NF-
B activation induced by
tumor necrosis factor-
; however, MG-115 had no effect on NF-
B
activation during oxidative stress.
ConclusionsThis study demonstrated a stimulus-specific
mechanism of NF-
B activation in endothelial cells
that acts independently of I
B
degradation and may require
tyrosine phosphorylation.
Key Words: cardiopulmonary bypass ischemia reperfusion endothelium
| Introduction |
|---|
|
|
|---|
During reperfusion, endothelial cells are critical in
recruiting and activating neutrophils, the principal cause of
acute inflammation.2 In response to septic insults,
endothelial cells undergo a phenotypic change leading
to the synthesis of neutrophil adhesion molecules (eg, E-selectin
[CD62E]) and neutrophil chemotactic agents (eg, interleukin
[IL]-8).3 4 This transient transcriptional response is
mediated, in part, by Rel/nuclear factor
B
(NF-
B).5 In quiescent endothelium,
NF-
B is held inactive within the cytoplasm by interaction with
inhibitor
B (I
B
) or other I
B family members.6
After stimulation with tumor necrosis factor (TNF)-
,
lipopolysaccharide (LPS), or IL-1, I
B
undergoes
rapid phosphorylation on serine residues 32 and 36;
this signals the proteolytic degradation of I
B
in
proteasomes.7 The dissociation of I
B
from NF-
B
exposes the nuclear localization signal8 on NF-
B, which
directs the translocation of the transcription factor to the nucleus to
promote the expression of genes that mediate inflammatory
reactions.9 NF-
Bmediated regulation of inflammatory
gene expression in human endothelial cells during
oxidative stress, however, is not defined.
In this study, we demonstrated that NF-
B activation occurs in
human hearts subjected to ischemia and reperfusion during
surgical procedures using cardiopulmonary bypass. In addition,
we showed in vitro that NF-
B activation occurs in cultured human
endothelial cells treated with a reactive oxygen
intermediate (H2O2) and in
cultures exposed to hypoxia followed by
reoxygenation. Unlike NF-
B activation induced by
TNF-
, IL-l, or LPS, NF-
B activation under conditions of oxidative
stress is achieved without measurable degradation of I
B
and may
involve tyrosine phosphorylation.
| Methods |
|---|
|
|
|---|
Human Cardiac Tissue Procurement
Right auricular tissue from patients undergoing coronary
artery bypass grafting was obtained during cannulation of the right
atrium in preparation for cardiopulmonary bypass (CPB).
Skeletal muscle samples were obtained from the intercostal muscle.
Samples were obtained before the start of cardioplegia and cardiac
arrest and 45 minutes after the patient was taken off bypass. All
tissues were immediately snap-frozen in liquid nitrogen in the
operating room. Frozen tissue samples, 0.25 to 0.5 g, were then
ground to a fine powder and suspended in 4.0 mL of buffer containing
0.06% Nonidet P-40, 150 mmol/L NaCl, 10 mmol/L HEPES,
1 mmol/L EDTA, and 0.5 mmol/L PMSF. The solution was
then homogenized and centrifuged for 15 s. The
pellet was discarded, and the supernatant was cooled to 4°C. The
supernatant was then centrifuged again for 15 s. The
pellet was resuspended in 40 µL of buffer containing (in
mmol/L): NaCl 420, HEPES 20, EDTA 0.2,
MgCl2 1.2, PMSF 0.5, and DDT 0.5 and 25%
glycerol, 5 µg/mL aprotinin, and 5 µg/mL leupeptin at 4°C for 20
minutes. This solution was then centrifuged for 5 minutes, the
pellet was discarded, and the supernatant, containing nuclear proteins,
was frozen at -70°C. Samples were analyzed for NF-
B as
described below. This study was approved by the Human Subjects
Committee of the University of Washington.
Hypoxia and Reoxygenation
Normoxic control cells were maintained at 37°C in a standard
incubator at room air oxygen tension (21% oxygen; designated
normoxia). To expose HUVECs to hypoxia, cultures were placed in
a controlled environmental chamber (Coy Laboratory Products) at
37°C and maintained at an oxygen tension of 2% to 3%. Oxygen
content in the media over HUVECs equilibrated with the hypoxic
environment of the chamber within 10 minutes, as measured by a Clark
electrode (data not shown). To expose HUVECs to hypoxia and
reoxygenation, cultures were removed from the
hypoxia chamber and placed in a normoxic incubator for
designated periods of time.
Electrophoretic Mobility Shift Assay
Third-passage HUVEC monolayers in 100-mm2
plates were exposed to 2 hours of hypoxia followed by
reoxygenation,
H2O2 (100 to 500
µmol/L), pervanadate (100 to 200 µmol/L), or TNF-
(100
U/mL) for designated time periods. Nuclear protein extractions were
performed using a modification of the technique of Dignam et
al,10A as previously described.11
Approximately 10 µg of nuclear protein was incubated in a binding
reaction with a double-stranded, 32P-end-labeled
oligonucleotide containing the human consensus NF-
B
binding sequence 5'-GCCATTGGGGATTTCCTCTTTACTGG-3'
(Promega). Binding reactions occurred at room temperature for 20
minutes. Proteins were resolved on 6% nondenaturing
polyacrylamide gels at 100 V for 1 to 2 hours in a 0.5%
Tris-boric acid-EDTA solution. The gels were dried and
autoradiographed.
Western Blot Analysis
Confluent HUVEC monolayers on 100-mm2
plates were treated with conditions of oxidative stress or TNF-
in
the manner described above. Cytoplasmic extracts were obtained using a
modified lysis buffer,5 and total protein concentration
was determined using a standard protein assay. Approximately 20 µg of
protein was loaded on SDS-PAGE gels and resolved at 100 V for 2 hours.
After transfer to a polyvinylidene difluoride membrane, the
membrane was stained with Coomassie blue to determine equal protein
transfer. The membranes were then incubated with anti-I
B
polyclonal antibody (Santa Cruz Biotechnology) at 1:1000 dilution for 2
hours. A HRP-conjugated secondary antibody was applied for 1 hour, and
the proteins were visualized using Amersham enhanced
chemiluminescent reagents and
autoradiography.
| Results |
|---|
|
|
|---|
B in human tissue under
conditions of oxidative stress, cardiac and skeletal muscle samples
were acquired before patients were placed on CPB and after reperfusion
of the heart for 45 minutes, after the patient was taken off CPB. We
chose right atrial tissue because this tissue receives the least amount
of cardioplegia during CPB, and the anterior location of the right
atrium makes it less likely to be cooled to a temperature approaching
4°C; previously, we demonstrated that NF-
B can be
activated at temperatures lower than 37°C but not at those
4°C.12 As shown in Figure 1
B was prominently
activated in human atrial tissue after 45 minutes of
reperfusion of the ischemic heart. However, skeletal muscle
obtained from the same patient at the same time points but not exposed
to ischemia and reperfusion showed no evidence of NF-
B
activation.
|
To define more specifically mechanisms of oxidative stressinduced
NF-
B activation, HUVECs were reoxygenated after a 2-hour
period of hypoxia and treated with
H2O2 or pervanadate.
Also, HUVECs were treated with medium alone or medium containing
TNF-
(100 U/mL) for 2 hours as a control stimulus of NF-
B
activation. In each experiment, either nuclear proteins were extracted
for electrophoretic mobility shift assays (EMSAs) to determine NF-
B
activation or cytoplasmic proteins were extracted for Western blotting
to determine the presence or absence of I
B
. As shown in Figure 2A
, TNF-
induced rapid degradation of
I
B
protein, with concomitant nuclear translocation of NF-
B
within 5 to 10 minutes of the addition of TNF-
; complete I
B
degradation was noted by 15 minutes, with the reappearance of I
B
in the cytoplasm by 1 hour during continuous exposure to TNF-
.
Similar results were obtained when cells were treated with IL-1 (10
U/mL) or LPS (100 ng/mL) (data not shown). HUVECs exposed to 2
hours of hypoxia followed by reoxygenation for
various periods of time also demonstrated rapid nuclear translocation
of NF-
B within 15 minutes after reoxygenation was
started (Figure 2B
). Similarly, rapid nuclear translocation of
NF-
B occurred in HUVECs treated with
H2O2 (Figure 2C
).
However, in contrast to the treatment of HUVECs with TNF-
,
reoxygenation of hypoxic HUVECs (Figure 2B
) and
treatment of HUVECs with
H2O2 (Figure 2C
) did
not result in degradation of I
B
.
|
Tyrosine phosphorylation of I
B
in Jurkat
T-cells treated with pervanadate reportedly prevents I
B
degradation.13 Pervanadate, a tyrosine phosphatase
inhibitor, is composed of
H2O2 and vanadate.
Pervanadate thus preserves transient tyrosine
phosphorylation of proteins and potentiates signal
transduction pathways involving tyrosine kinases. As shown in Figure 2D
, pervanadate treatment initiated rapid and pronounced nuclear
translocation of NF-
B, without associated degradation of I
B
.
To exclude the possibility that oxidative stress induces NF-
B
activation through the degradation of NF-
B cytoplasmic
inhibitors other than I
B
, Western blots (using
polyclonal antisera to I
B family members I
Bß or I
B
) were
performed on cytoplasmic proteins from HUVECs treated with pervanadate.
Neither I
Bß nor I
B
were degraded in HUVECs exposed to
oxidative stress (data not shown).
Because oxidative stress seems to activate NF-
B without
apparent degradation of I
B proteins, we reasoned that
inhibitors of I
B degradation in the proteasome should
have no effect on oxidative stress-induced NF-
B activation. To test
this hypothesis, proteasome function in HUVECs was inhibited with the
peptide aldehydes MG 115 or
N-acetyl-leucine-leucine-not leucine
(ALLN).14 15 As shown in Figure 3A
, MG 115 (30 µmol/L) predictably
blocked TNF-
induced activation of NF-
B; it had no effect,
however, on NF-
B activation in response to oxidative stress in
HUVECs treated with pervanadate. Identical results were obtained with
ALLN (data not shown; 4 separate experiments). These results further
support the possibility that oxidative stress-induced NF-
B
translocation to the nucleus can occur independently of I
B
degradation, suggesting that alternate pathways of NF-
B activation
exist in cardiovascular cells sustaining I/R
injury.
|
| Discussion |
|---|
|
|
|---|
B in response to diverse stimuli. It is unknown, however,
whether each stimulus activates NF-
B through the same
signaling pathway or through different and unique pathways. Our
findings indicate that in HUVECs, oxidative stress activates
NF-
B through a mechanism that does not require I
B
degradation,
a biochemical event that is required for TNF-
induced NF-
B
activation. I
Bß or I
B
degradation, as measured by Western
blot analysis with polyclonal antibodies specific for each
inhibitor protein, also was not observed in HUVECs exposed
to oxidative stress (data not shown). Although not degraded, I
B is
most likely modified in some fashion during oxidative stress to cause
I
B to dissociate from NF-
B, exposing a nuclear localization
signal in NF-
B as a prerequisite to nuclear translocation of
NF-
B.8 This conjecture, however, was not examined in
the present study.
TNF-
stimulation of HUVECs results in rapid
phosphorylation of I
B
serine residues 32 and 36
by a multimeric I
B kinase complex, which is
activated by other upstream kinases.7 16 Serine
phosphorylation of I
B
is followed by addition of
a ubiquitin protein to I
B
and degradation in the
proteasome.7 Recent reports have demonstrated that I
B
can also be phosphorylated on a tyrosine residue at
position 42 of I
B
, which is in close proximity to the 2 serine
phosphoacceptor sites.13 17
Tyrosine-phosphorylated I
B
is protected from
TNF-
induced degradation, although the mechanism of this protective
effect is not known. In Jurkat T-cells, tyrosine
phosphorylation of I
B
is observed after exposure
of this cell line to pervanadate or to hypoxia followed by
reoxygenation, and tyrosine
phosphorylation produces dissociation of
tyrosine-phosphorylated I
B
from
NF-
B.18 Tyrosine phosphorylation of
I
B
in Jurkat T-cells after exposure to hypoxia only has
been observed as well.19 In the study with hypoxic Jurkat
T-cells, I
B
degradation was observed 60 minutes after the onset
of hypoxia. In contrast, we did not observe I
B
degradation in HUVECs after 60 minutes of hypoxia. Moreover,
NF-
B activation in hypoxic HUVECs occurs within 15 minutes of the
onset of reoxygenation of hypoxic cells. Therefore, we
are unable to relate the response of Jurkat T-cells to hypoxia
to the human endothelial cell activation induced by
oxidative stress.
The results we obtained in vitro may be relevant to I/R injury in
vivo. In patients undergoing open heart surgery, we assayed right
atrial tissue samples for NF-
B activation. Tissue was obtained
before CPB and 45 minutes after CPB was discontinued. We showed that
NF-
B is activated in human hearts reperfused for 45 minutes
after the discontinuation of CPB, but not in skeletal muscle samples
that were continuously perfused and oxygenated. This is the
first demonstration of NF-
B in vivo in human hearts with I/R
injury.
In summary, our results suggest that oxidative stress in human
vascular cells may activate the proinflammatory transcription
factor NF-
B through an alternative pathway independent of I
B
degradation. Thus, the inflammatory response to oxidative stress
involving NF-
B and occurring during I/R injury may be inhibited
without compromising a cytokine-induced, NF-
Bmediated
inflammatory response to infection.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
2. Winn RK, Liggitt D, Vedder NB, Paulson JC, Harlan JM. Anti-P-selectin monoclonal antibody attenuates reperfusion injury to the rabbit ear. J Clin Invest. 1993;92:20422047.
3. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation. 1990;50:537544.[Medline] [Order article via Infotrieve]
4.
Pober JS, Cotran RS. Cytokines and
endothelial cell biology. Physiol Rev. 1990;70:427451.
5.
Read MA, Whitley MZ, Williams AJ, Collins T.
NF-
B and I
B
: an inducible regulatory system in
endothelial activation. J Exp Med. 1994;179:503512.
6.
Beg AA, Baldwin AS Jr. The I
B proteins:
multifunctional regulators of Rel/NF-
B transcription factors.
Genes Dev. 1993;7:20642070.
7.
Brown K, Gerstberger S, Carlson L, Franzoso G,
Siebenlist U. Control of I
B
proteolysis by site specific,
signal induced phosphorylation. Science. 1995;267:14851488.
8.
Jans DA, Hubner S. Regulation of protein transport to
the nucleus: central role of phosphorylation.
Physiol Rev. 1996;76:651685.
9.
Baeuerle PA, Baltimore D. NF-
B: 10 years
after. Cell. 1996;87:1320.[Medline]
[Order article via Infotrieve]
10. Magnuson DK, Weintraub A, Pohlman TH, Maier RV. Human endothelial cell adhesiveness for neutrophils, induced by Escherichia coli lipopolysaccharide in vitro, is inhibited by Bacteroides fragilis lipopolysaccharide. J Immunol. 1989;143:30253030.[Abstract]
10. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiated by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:14751489.
11.
Montgomery KF, Osborn L, Hession C, Tizard R, Goff D,
Vassallo C, Tarr PI, Bomsztyk K, Lobb R, Harlan JM, Pohlman TH.
Activation of endothelial-leukocyte adhesion molecule 1
(ELAM-1) gene transcription. Proc Natl Acad Sci U S A. 1991;88:65236527.
12. Haddix TL, Pohlman TH, Noel RF, Sato TT, Boyle EM Jr, Verrier ED. Hypothermia inhibits human E-selectin transcription. J Surg Res. 1996;64:176183.[Medline] [Order article via Infotrieve]
13.
Singh S, Darnay BG, Aggarwal BB. Site-specific tyrosine
phosphorylation of I
B
negatively regulates
its inducible phosphorylation and degradation.
J Biol Chem. 1996;271:3104931054.
14.
Zen K, Karsan A, Eunson T, Yee E, Harlan JM.
Lipopolysaccharide-induced NF-
B activation in human
endothelial cells involves degradation of I
B
but
not I
Bß. Exp Cell Res. 1998;243:425433.[Medline]
[Order article via Infotrieve]
15.
Hellerbrand C, Jobin C, Iimuro Y, Licato L,
Sartor RB, Brenner DA. Inhibition of NF-
B in activated
rat hepatic stellate cells by proteasome inhibitors and an
I
B super-repressor. Hepatology. 1998;27:12851295.[Medline]
[Order article via Infotrieve]
16.
Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S,
Baeuerle PA. Phosphorylation of human I
B
on
serines 32 and 36 controls I
B
proteolysis and NF-
B activation
in response to diverse stimuli. EMBO J. 1995;14:28762883.[Medline]
[Order article via Infotrieve]
17.
Abu-Amer Y, Ross FP, McHugh KP, Livolsi A, Peyron JF,
Teitelbaum SL. Tumor necrosis factor-
activation of nuclear
transcription factor-
B in marrow macrophages is mediated by
c-Src tyrosine phosphorylation of I
B
.
J Biol Chem. 1998;273:2941729423.
18.
Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB,
Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA,
Peyron JF. Tyrosine phosphorylation of I
B
activates NF-
B without proteolytic degradation of I
B
.
Cell. 1996;86:787798.[Medline]
[Order article via Infotrieve]
19.
Koong AC, Chen EY, Giaccia AJ. Hypoxia
causes the activation of nuclear factor
B through the
phosphorylation of I
B
on tyrosine residues.
Cancer Res. 1994;54:14251430.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |